ストックスクリーナーアプリを入手
3.413
3.86%
-0.137
前日終値:
$3.55
開ける：
$3.562
24時間の取引高:
29,474
Relative Volume:
0.54
時価総額：
$2.80M
収益：
$4.79M
当期純損益:
$-13.42M
株価収益率:
-1.2831
EPS:
-2.66
ネットキャッシュフロー:
$-10.30M
1週間 パフォーマンス:
-5.46%
1か月 パフォーマンス:
-9.47%
6か月 パフォーマンス:
-18.93%
1年 パフォーマンス:
-60.38%
1日の値動き範囲:
$3.39
$3.70
1週間の範囲:
$3.3703
$3.70
52週間の値動き範囲:
$2.85
$29.43
Qualigen Therapeutics Inc Stock (QLGN) Company Profile
名前
Qualigen Therapeutics Inc
セクター
電話
(760) 918-9165
住所
2042 CORTE DEL NOGAL, CALIFORNIA
QLGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QLGN
Qualigen Therapeutics Inc
|
3.413 | 2.80M | 4.79M | -13.42M | -10.30M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Qualigen Therapeutics Inc (QLGN) 最新ニュース
Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Up 3.3% – Here’s Why - Defense World
Qualigen Therapeutics Faces Nasdaq Delisting Notification - MSN
Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 2.1% – Should You Sell? - Defense World
Qualigen Therapeutics Receives Nasdaq Deficiency Notice - marketscreener.com
Qualigen Therapeutics, Inc. receives expected notification of de - GuruFocus
Qualigen Therapeutics receives Nasdaq notice regarding delayed Form 10-Q - MSN
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q | QLGN Stock News - GuruFocus
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q - The Manila Times
Qualigen Therapeutics, Inc. Receives Expected Notification Of Deficiency From Nasdaq Related To Delayed Filing Of Quarterly Report On Form 10-Q - marketscreener.com
Qualigen Therapeutics faces potential Nasdaq delisting - Investing.com
Qualigen Therapeutics, Inc. Faces Potential Delisting from Nasdaq Due to Filing Deficiency - Nasdaq
Qualigen Therapeutics, Inc. receives expected notification - GlobeNewswire
Qualigen Gets Nasdaq Warning: Missing Q1 Report Puts Stock Listing in Jeopardy - Stock Titan
Qualigen Therapeutics (QLGN) Faces Nasdaq Compliance Challenge | - GuruFocus
Qualigen Therapeutics, Inc. Receives Notification of Deficiency - GuruFocus
Qualigen Therapeutics Faces Nasdaq Delisting Threat - TipRanks
Qualigen Therapeutics, Inc. Faces Nasdaq Delisting Due to Late Filing of 2024 Form 10-K - Nasdaq
Qualigen Therapeutics, Inc. Receives Notification of - GlobeNewswire
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K - TradingView
QLGN stock touches 52-week low at $2.9 amid market challenges By Investing.com - Investing.com South Africa
QLGN stock touches 52-week low at $2.9 amid market challenges - Investing.com India
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Qualigen Therapeutics Delays Yearly Financial Report - TipRanks
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme - GlobeNewswire
Qualigen Therapeutics to acquire Marizyme in strategic move - Investing.com
Qualigen Therapeutics to acquire Marizyme in strategic move By Investing.com - Investing.com South Africa
Medical Breakthrough: Qualigen's Strategic Move to Transform $10B Heart Surgery Market - Stock Titan
Qualigen Therapeutics, Inc. (NASDAQ:QLGN) Short Interest Up 49.4% in January - Defense World
Qualigen to invest in NanoSynex, stock tumbles 21% - MSN
Qualigen Therapeutics Invests in NanoSynex’s Growth - TipRanks
Qualigen to participate in next funding round for NanoSynex - GlobeNewswire
This Breakthrough Could Cut Antibiotic Testing Time in HalfQualigen's Strategic Investment - StockTitan
Microbiomes Market to Grow by USD 1.13 Billion (2024-2028), Driven by Rising Disease Prevalence; AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Qualigen Therapeutics (NASDAQ:QLGN) Stock Price Down 5.2% – Time to Sell? - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Shares Down 5.2% – Here’s Why - Defense World
Qualigen Therapeutics (NASDAQ:QLGN) Trading Down 7.8% – Time to Sell? - Defense World
SEC Form S-1 filed by Qualigen Therapeutics Inc. - Quantisnow
Qualigen Therapeutics Announces Regained Compliance with - GlobeNewswire
Univest Securities, LLC Announces Successful Closing of - GlobeNewswire
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares - GlobeNewswire
Qualigen Therapeutics appoints new board member - Investing.com
Qualigen Therapeutics Appoints Graydon Bensler to Board - TipRanks
QLGN Stock Touches 52-Week Low at $3.71 Amid Market Challenges - Investing.com
Qualigen Therapeutics announces 1-for-50 reverse stock split - Investing.com
QLGN stock touches 52-week high at $5.05 amid market fluctuations - Investing.com
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 - GlobeNewswire
Stocks Under Ten Cents to Watch in October 2024 CNSP, QLGN, AKTS, CBDW, RJDG - openPR.com
QLGN stock touches 52-week low at $0.11 amid market challenges - Investing.com
Qualigen Therapeutics faces Nasdaq delisting notice - Investing.com
Qualigen Therapeutics appoints new leadership amid strategic shift By Investing.com - Investing.com South Africa
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel - GlobeNewswire
Qualigen Therapeutics Inc (QLGN) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
0.23%
大文字化:
|
ボリューム (24 時間):